Abstract
Protracted, 24-hour, continuous-infusion cisplatin at a dose rate of 5 mg/m2/day was administered to 25 patients with advanced measurable colorectal cancer. All patients had previously received 5-FU administered on the same schedule. Sixteen patients received the infusion for greater than or equal to 14 days and were considered evaluable for response assessment. No patient achieved a response.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Ambulatory Care
-
Cisplatin / administration & dosage*
-
Cisplatin / adverse effects
-
Colonic Neoplasms / drug therapy*
-
Colonic Neoplasms / pathology
-
Drug Evaluation
-
Humans
-
Infusions, Parenteral
-
Liver Neoplasms / secondary
-
Lung Neoplasms / secondary
-
Peritoneal Neoplasms / secondary
-
Rectal Neoplasms / drug therapy*
-
Rectal Neoplasms / pathology